Equity Overview
Price & Market Data
Price: $0.842
Daily Change: +$0.0026 / 0.31%
Daily Range: $0 - $0
Market Cap: $30,451,436
Daily Volume: 0
Performance Metrics
1 Week: 0.24%
1 Month: -4.43%
3 Months: -24.82%
6 Months: -23.11%
1 Year: -40.70%
YTD: -29.83%
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.